Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study-Reference-Cited by-同舟云学术

Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study

Published:2020-09 Issue:9 Volume:109 Page:2729-2734
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Itin Constantin,Komargodski Rinat,Domb Abraham J.,Hoffman Amnon

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference63 articles.

1. Electrostatic medium effects and formal quantum structure-activity relationships in apomorphines interacting with D1 and D2 dopamine receptors;Gomez-Jeria;Int J Quantum Chem,1997

2. Levodopa therapy for Parkinson disease: a look backward and forward;LeWitt;Neurology,2016

3. Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis;Campbell;Eur J Pharmacol,1980

4. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations;Manson;Brain,2001

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanotechnology-based mucoadhesive and mucus-penetrating drug-delivery systems for transbuccal drug delivery;Nanomedicine;2023-09

2. Oral Health and Use of Novel Transbuccal Drug Delivery Systems in Patients with Alzheimer’s and Parkinson’s Disease: A Review;Applied Sciences;2023-04-15

3. The Clinical Development of Levodopa Inhalation Powder;Clinical Neuropharmacology;2023-01-29

4. Nanocarriers-based noninvasive approaches for dementia;Nanomedicine-Based Approaches for the Treatment of Dementia;2023

5. On demand therapy for Parkinson’s disease patients: Opportunities and choices;Postgraduate Medicine;2021-06-30